Coming Soon

Expected availability announced soon

This course is in active development. Preview the scope below and create a free account to be notified the moment it goes live.

Notify me

Continuing Education Coming Soon

CE Controlled Substance Pharmacist

Pharmacists learn current DEA registration requirements, prescription drug monitoring, corresponding responsibility, red‑flag diversion indicators, partial fills, and emergency dispensing, ensuring compliant, safe controlled‑substance practice in clinical settings.

Who Should Take This

Licensed pharmacists who dispense or oversee controlled substances in community, hospital, or specialty settings benefit from this refresher. They typically have at least two years of practice experience and seek to stay current on regulatory changes, diversion detection, and medication‑assisted treatment compliance.

What's Included in AccelaStudy® AI

Adaptive Knowledge Graph

Practice Questions

Lesson Modules

Console Simulator Labs

Exam Tips & Strategy

20 Activity Formats

Course Outline

66 learning goals

1 DEA Registration and Regulatory Framework

2 topics

Registration and scheduling

Identify the five DEA schedules of controlled substances and the criteria used to classify drugs including abuse potential, accepted medical use, and physical or psychological dependence liability.
Explain DEA registration requirements for pharmacies including Form 224, registration categories, renewal timelines, and the process for reporting theft or loss on DEA Form 106.
Describe the DEA number validation algorithm and explain how to verify prescriber DEA numbers to detect potentially forged prescriptions.

Recordkeeping and inventory

Identify controlled substance inventory requirements including biennial inventory procedures, perpetual inventory systems, and recordkeeping retention periods under DEA regulations.
Explain the ordering process for Schedule II controlled substances using DEA Form 222 and the CSOS electronic ordering system including security requirements and error correction.
Analyze controlled substance inventory discrepancies to determine whether they indicate diversion, documentation errors, or system malfunctions and determine appropriate reporting actions.
Design a controlled substance accountability system for a pharmacy that integrates perpetual inventory, receipt verification, dispensing documentation, waste procedures, and discrepancy investigation.

2 Prescription Drug Monitoring Programs

2 topics

PDMP mandates and operations

Identify the purpose and components of state Prescription Drug Monitoring Programs including data collection, reporting schedules, and access authorization levels for different healthcare providers.
Explain mandatory PDMP query requirements for pharmacists including when queries must be performed, which schedules are covered, and documentation of query results.
Describe interstate PDMP data sharing through PMP InterConnect and the clinical benefits and privacy challenges of cross-state prescription monitoring.

PDMP data interpretation

Analyze PDMP reports to identify concerning patterns including multiple prescriber episodes, overlapping opioid and benzodiazepine prescriptions, escalating doses, and pharmacy shopping.
Evaluate PDMP data in the context of legitimate pain management to distinguish appropriate high-dose opioid therapy from potential misuse or diversion indicators.
Identify the limitations of PDMP data including reporting delays, out-of-state gaps, veterinary prescriptions, and the inability to capture illicit drug use or medication sharing.
Design a pharmacy PDMP integration workflow that incorporates mandatory queries into dispensing operations, documents clinical decisions, and establishes escalation protocols for concerning findings.

3 Corresponding Responsibility Doctrine

2 topics

Legal framework and application

Identify the corresponding responsibility doctrine under 21 CFR 1306.04 requiring pharmacists to ensure controlled substance prescriptions serve a legitimate medical purpose.
Explain the pharmacist's duty to exercise professional judgment when evaluating controlled substance prescriptions and the circumstances under which refusal to fill is legally supported.
Describe the legal consequences for pharmacists who knowingly fill illegitimate controlled substance prescriptions including criminal liability, license revocation, and civil penalties.

Clinical application of corresponding responsibility

Analyze controlled substance prescription scenarios to determine whether red flags are present and whether additional verification with the prescriber is warranted.
Evaluate the balance between patient access to legitimate pain management and the pharmacist's responsibility to prevent controlled substance diversion in challenging clinical situations.
Identify documentation practices for corresponding responsibility assessments including recording red flag evaluations, prescriber verification calls, and reasons for dispensing or refusing to fill.
Design a pharmacy policy for corresponding responsibility that provides clear guidance for staff on red flag assessment, prescriber communication, refusal documentation, and patient referral.

4 Red Flag Indicators for Diversion

2 topics

Identifying red flags

Identify red flag indicators for controlled substance diversion including early refill requests, cash payment for controlled substances while using insurance for other medications, and long-distance travel to pharmacy.
Describe prescription forgery indicators including altered quantities, unauthorized refill additions, stolen prescription pads, and common patterns in fraudulent prescriptions.
Explain the holy trinity combination of opioids, benzodiazepines, and muscle relaxants as a red flag pattern and the clinical dangers of concurrent prescribing.

Response to red flags

Analyze complex dispensing scenarios involving multiple red flags to determine whether to fill, partially fill, refuse, or seek additional prescriber verification.
Evaluate internal pharmacy diversion indicators including inventory discrepancies, unusual waste patterns, employee behavior changes, and systematic approaches to staff monitoring.
Design a red flag assessment checklist for pharmacy staff that standardizes the evaluation of controlled substance prescriptions and documents clinical decision-making for each dispensing event.

5 Partial Fills and Emergency Dispensing

2 topics

Partial fill regulations

Identify the partial fill provisions for Schedule II controlled substances under CARA including the 30-day completion window and documentation requirements.
Explain the differences between partial fill rules for Schedule II versus Schedules III-V controlled substances including remaining quantity tracking and refill limitations.
Describe the partial fill provisions specific to long-term care facility residents and terminally ill patients including extended fill periods and prescriber notification requirements.

Emergency dispensing

Identify the DEA requirements for emergency oral prescriptions of Schedule II controlled substances including the prescriber verification process and 7-day follow-up written prescription requirement.
Explain the pharmacist's authority to provide emergency controlled substance supplies and the state-specific limitations on quantity, duration, and schedule coverage.
Analyze emergency dispensing scenarios to determine whether the situation qualifies for emergency supply and what documentation and prescriber notification are required.
Design an emergency dispensing protocol for a pharmacy that addresses Schedule II oral prescriptions, emergency supplies for maintenance medications, after-hours scenarios, and documentation templates.

6 Naloxone Access and Overdose Prevention

2 topics

Naloxone dispensing authority

Identify the legal mechanisms for pharmacist-dispensed naloxone including statewide standing orders, collaborative practice agreements, pharmacist prescriptive authority, and OTC availability.
Explain the pharmacology of naloxone including its mechanism as an opioid antagonist, available formulations (intranasal, intramuscular, auto-injector), duration of action, and precipitated withdrawal risk.
Describe Good Samaritan laws and naloxone immunity provisions that protect laypersons and healthcare providers who administer naloxone in emergency opioid overdose situations.

Naloxone counseling and programs

Analyze patient risk factors for opioid overdose including high-dose prescriptions, concurrent benzodiazepine use, substance use history, and post-incarceration or post-treatment vulnerability.
Evaluate naloxone co-prescribing guidelines and determine which patients receiving opioid prescriptions should be offered naloxone based on CDC recommendations and risk stratification.
Identify the counseling points for naloxone recipients including recognizing overdose signs, calling 911, proper administration technique, rescue breathing, and the possibility of repeat dosing.
Design a pharmacy-based naloxone distribution program including patient identification strategies, counseling protocols, community partnerships, outcome tracking, and funding models.

7 Medication-Assisted Treatment for Opioid Use Disorder

2 topics

Buprenorphine and prescribing changes

Identify the medications FDA-approved for opioid use disorder treatment including buprenorphine formulations, methadone, and extended-release naltrexone and their DEA scheduling.
Explain the regulatory evolution of buprenorphine prescribing from DATA 2000 X-waiver requirements through the MATE Act training mandates and the elimination of the X-waiver in 2023.
Describe the pharmacology of buprenorphine as a partial opioid agonist including ceiling effect, precipitated withdrawal risk, sublingual and injectable formulations, and naloxone combination rationale.
Analyze buprenorphine induction protocols including patient assessment, timing relative to last opioid use, micro-dosing strategies, and dose stabilization procedures.

Methadone and naltrexone programs

Explain the regulatory framework for methadone dispensing through opioid treatment programs including take-home dose criteria, counseling requirements, and SAMHSA certification.
Describe the role of extended-release naltrexone in opioid use disorder treatment including required opioid-free period, administration logistics, and adherence monitoring strategies.
Evaluate the pharmacist's role in MAT support including buprenorphine dispensing, patient monitoring, adherence counseling, drug interaction screening, and coordination with prescribers.
Design a pharmacy-based MAT support program that integrates buprenorphine dispensing, PDMP monitoring, naloxone co-dispensing, patient education, and referral pathways to behavioral health services.

8 Prescription Validity and Processing

2 topics

Prescription requirements by schedule

Identify the prescription requirements for each controlled substance schedule including written versus oral prescriptions, refill limitations, and prescription validity periods.
Explain electronic prescribing requirements for controlled substances including EPCS certification, identity proofing, two-factor authentication, and audit trail requirements.
Describe mid-level prescriber authority for controlled substances including nurse practitioner, physician assistant, and optometrist prescribing limitations by state and DEA requirements.

Prescription processing challenges

Analyze controlled substance prescription validity issues including expired prescriptions, quantity limits, early refill calculations, and transfers between pharmacies.
Evaluate the appropriateness of controlled substance dose and quantity in the context of patient-specific factors, diagnosis, and prescriber specialty to fulfill corresponding responsibility.
Design a controlled substance prescription processing checklist that pharmacy technicians and pharmacists can use to verify prescription validity, screen for red flags, and document clinical decisions.

9 Controlled Substance Disposal and Drug Take-Back

2 topics

Disposal regulations

Identify DEA-authorized methods for controlled substance disposal by pharmacies including reverse distribution, on-site destruction, and drug take-back collection.
Explain the DEA take-back program regulations including authorized collector registration, collection receptacle specifications, inner liner requirements, and law enforcement mail-back options.
Describe the documentation requirements for controlled substance destruction including witness requirements, DEA Form 41 procedures, and recordkeeping for on-site versus reverse distributor disposal.

Take-back program management

Analyze the regulatory requirements and liability considerations for pharmacies operating as authorized drug take-back collectors under DEA regulations.
Design a pharmacy drug take-back program that addresses DEA collector registration, receptacle placement, patient communication, inner liner handling, and reverse distributor coordination.

10 Opioid Stewardship and Harm Reduction

2 topics

Opioid stewardship principles

Identify the components of pharmacy-based opioid stewardship including morphine milligram equivalent calculations, duration-of-therapy limits, and concurrent benzodiazepine screening.
Explain opioid equianalgesic dosing calculations and the clinical significance of the 90 MME per day threshold identified in CDC opioid prescribing guidelines.
Describe harm reduction strategies that pharmacists can implement including syringe services program participation, fentanyl test strip distribution, and wound care supply provision.

Stewardship program implementation

Analyze prescription opioid risk factors including concurrent CNS depressants, history of substance use disorder, mental health conditions, and sleep-disordered breathing to guide dispensing decisions.
Evaluate the effectiveness of pharmacy opioid stewardship interventions including prescriber feedback, patient risk assessments, and naloxone co-dispensing on opioid-related outcomes.
Design a comprehensive pharmacy opioid stewardship program integrating PDMP review, MME calculations, prescriber outreach, naloxone dispensing, and harm reduction services.

Scope

Included Topics

DEA registration requirements for pharmacies and pharmacists including registration types, renewal processes, state-level controlled substance licenses, and DEA number validation using the Luhn algorithm.
Prescription Drug Monitoring Program requirements including state PDMP mandates, prescriber and dispenser obligations, interstate data sharing, and PDMP integration with pharmacy management systems.
Corresponding responsibility doctrine requiring pharmacists to ensure controlled substance prescriptions are issued for legitimate medical purposes by authorized prescribers acting within their professional practice.
Red flag indicators for controlled substance diversion including early refills, multiple prescribers, distant patients, cash payment patterns, specific drug-dose combinations, and forged prescription detection.
Partial fill regulations for Schedule II controlled substances including partial fill provisions under the Comprehensive Addiction and Recovery Act for all patients and hospice-specific provisions.
Emergency dispensing of controlled substances including DEA-authorized emergency oral prescriptions, 72-hour emergency supplies, and documentation and follow-up requirements.
Naloxone standing orders and pharmacist prescriptive authority for naloxone including state-level standing order provisions, patient and third-party dispensing, training requirements, and Good Samaritan protections.
Medication-assisted treatment for opioid use disorder including buprenorphine prescribing (DATA 2000 and MATE Act changes), methadone dispensing through OTPs, and extended-release naltrexone.

Not Covered

Detailed pharmacology of controlled substances beyond what is needed for appropriate dispensing, monitoring, and counseling.
Law enforcement investigation techniques, forensic drug analysis, or prosecution procedures for drug diversion cases.
International controlled substance regulations or treaties beyond U.S. federal and state requirements.
Illicit drug manufacturing processes or clandestine laboratory identification.

CE Controlled Substance Pharmacist is coming soon

Adaptive learning that maps your knowledge and closes your gaps.

Create Free Account to Be Notified